Bristol-Myers Squibb Company (FRA:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 77.05B |
| Revenue (ttm) | 40.62B |
| Net Income (ttm) | 4.30B |
| Shares Out | n/a |
| EPS (ttm) | 2.12 |
| PE Ratio | 17.92 |
| Forward PE | 6.81 |
| Dividend | 2.24 (5.50%) |
| Ex-Dividend Date | Jul 3, 2025 |
| Volume | 1,061 |
| Average Volume | 2,373 |
| Open | 40.45 |
| Previous Close | 40.74 |
| Day's Range | 40.45 - 41.16 |
| 52-Week Range | 39.41 - 58.79 |
| Beta | n/a |
| RSI | 36.02 |
| Earnings Date | Jul 31, 2025 |
About Accolade
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
Financial Performance
Financial StatementsNews
Bristol Myers Squibb taps Cristian Massacesi as CMO
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development
Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In ...
Peering Into Bristol-Myers Squibb's Recent Short Interest
Bristol-Myers Squibb's (NYSE: BMY) short percent of float has risen 17.58% since its last report. The company recently reported that it has 39.45 million shares sold short , which is 1.94% of all reg...
A Look Into Bristol-Myers Squibb Inc's Price Over Earnings
In the current session, the stock is trading at $46.90, after a 0.45% spike. Over the past month, Bristol-Myers Squibb Inc. (NYSE: BMY) stock increased by 1.92% , and in the past year, by 7.33% . Wit...
FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks
Replimune Group, Inc. (NASDAQ: REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update . The clinical stage biotechnology company received an FDA Complete Response Lette...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
Applications supported by positive results from the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials, in which significantly more patients treated with Sotyktu achieved ACR20 response com...
Bristol Myers fails in late-stage trial for Merck-partnered anemia therapy in blood cancer
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial evaluating Reblozyl ® (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with...
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi) therapy in adult patients with my...
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
The companies' new effort would bypass traditional middlemen to cut the drug's monthly cost from a list price of around $606 to $346.
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis (apixaban) Option
The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) – (Pfizer NYSE: PFE) Alliance today announced a new direct-to-patient option for purchasing Eliquis (apixaban) via our Alliance’s patient resource Eliqu...
Bristol-Myers and Pfizer to offer 40% discount on blockbuster blood thinner Eliquis - report
Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE: BMY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzing...
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
Bristol-Myers Squibb & Co. (NYSE: BMY) is gearing up to announce its second-quarter 2025 earnings on July 31, with expectations for adjusted earnings of $1.585 per share on sales of $11.31 billion, a...
Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company
Sign up now: Procurement leaders convene to discuss resilient growth and innovation
Business Insider's July 30 virtual event features executives talking about procurement innovation strategies. The panel features experts from Bristol-Myers Squibb and Amazon Business.
Price Over Earnings Overview: Bristol-Myers Squibb
Looking into the current session, Bristol-Myers Squibb Inc. (NYSE: BMY) shares are trading at $47.05, after a 1.22% drop. Over the past month, the stock decreased by 3.08% , but over the past year, i...
IDEXX, DexCom lead S&P 500 healthcare gains in Q2; UnitedHealth and Bristol Myers Squibb among top laggards
Our bottom 5 stocks for the first half of 2025 and why we still own them
This is what it will take to for a turnaround in shares of Salesforce, Apple, Bristol Myers, DuPont and Danaher.